Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
IRWD 
Ironwood Pharmaceuticals Inc (IRWD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/04/2025: IRWD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -72.9% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 216.82M USD | Price to earnings Ratio 134 | 1Y Target Price 8.67 |
Price to earnings Ratio 134 | 1Y Target Price 8.67 | ||
Volume (30-day avg) 2677279 | Beta 0.3 | 52 Weeks Range 1.25 - 8.45 | Updated Date 04/6/2025 |
52 Weeks Range 1.25 - 8.45 | Updated Date 04/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.01 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 0.25% | Operating Margin (TTM) 34.86% |
Management Effectiveness
Return on Assets (TTM) 14.56% | Return on Equity (TTM) -574.72% |
Valuation
Trailing PE 134 | Forward PE 12.33 | Enterprise Value 727746638 | Price to Sales(TTM) 0.62 |
Enterprise Value 727746638 | Price to Sales(TTM) 0.62 | ||
Enterprise Value to Revenue 2.07 | Enterprise Value to EBITDA 7.26 | Shares Outstanding 161808992 | Shares Floating 123653150 |
Shares Outstanding 161808992 | Shares Floating 123653150 | ||
Percent Insiders 1.93 | Percent Institutions 102.52 |
Analyst Ratings
Rating 4.33 | Target Price 12.5 | Buy 2 | Strong Buy 3 |
Buy 2 | Strong Buy 3 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Ironwood Pharmaceuticals Inc
Company Overview
History and Background
Ironwood Pharmaceuticals Inc. was founded in 1998. The company initially focused on developing treatments for gastrointestinal (GI) diseases and has evolved to focus on commercializing and developing GI therapies.
Core Business Areas
- Gastrointestinal (GI) Therapeutics: Ironwood focuses on the development and commercialization of therapies for gastrointestinal diseases. This includes products that address conditions like irritable bowel syndrome with constipation (IBS-C).
Leadership and Structure
The leadership team includes a CEO, CFO, and other key executives with expertise in pharmaceuticals and business management. The organizational structure is typical of a pharmaceutical company, with departments focusing on research and development, commercialization, and operations.
Top Products and Market Share
Key Offerings
- Linzess/Constella (linaclotide): Linzess/Constella is a guanylate cyclase-C (GC-C) agonist used to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) in adults. It is commercialized in partnership with AbbVie in the US. Competitors include other IBS-C and CIC treatments such as Trulance (plecanatide) from Salix Pharmaceuticals.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated, with significant investments in research and development. The GI therapeutics market is driven by the prevalence of conditions like IBS-C and CIC and the demand for effective treatments.
Positioning
Ironwood Pharmaceuticals Inc. is positioned as a key player in the GI therapeutics market, particularly with its focus on Linzess/Constella. Its competitive advantage lies in its established presence in this market segment.
Total Addressable Market (TAM)
The total addressable market for IBS-C and CIC treatments is estimated to be several billion dollars. Ironwood is positioned to capture a significant portion of this TAM with Linzess/Constella.
Upturn SWOT Analysis
Strengths
- Established presence in the GI therapeutics market
- Partnership with AbbVie for Linzess/Constella
- Strong focus on research and development
Weaknesses
- Reliance on a limited number of products
- Competition from other GI therapeutics
- Dependence on partner AbbVie for Linzess revenue
Opportunities
- Expansion into new GI therapeutic areas
- Development of new formulations or indications for existing products
- Partnerships and collaborations for new product development
Threats
- Patent expiration of key products
- Increased competition from generics and new therapies
- Regulatory changes affecting drug pricing and reimbursement
Competitors and Market Share
Key Competitors
- SLXP
- ARDS
Competitive Landscape
Ironwood Pharmaceuticals Inc. faces competition from other companies in the GI therapeutics market, including Salix and Ardelyx. Its competitive advantage lies in the established market position of Linzess/Constella.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the sales of Linzess/Constella.
Future Projections: Future growth is dependent on the continued success of Linzess/Constella and the development and commercialization of new products.
Recent Initiatives: Recent initiatives include efforts to expand the market for Linzess/Constella and to advance the development of new GI therapies.
Summary
Ironwood Pharmaceuticals is heavily reliant on the success of Linzess/Constella, exhibiting both a strength and weakness. Their partnership with AbbVie is crucial, but this also presents a dependence. Future success depends on expanding their product pipeline and adapting to changing market dynamics and regulatory landscapes. There are growth opportunities if they diversify their revenue streams.
Similar Companies
ABBV
AbbVie Inc
ABBV
AbbVie Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance can change rapidly. Consult with a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ironwood Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2010-02-03 | CEO & Director Mr. Thomas A. McCourt | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 253 | Website https://www.ironwoodpharma.com |
Full time employees 253 | Website https://www.ironwoodpharma.com | ||
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.